The problem was resolved Thursday, when lawmakers sent a $240 million supplemental budget to Governor Maura Healey, which she ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

The popularity of GLP-1 drugs has insurance companies scrambling to satisfy consumer access while reining in exorbitant costs ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

This week, CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded. It's important to have a range of ...

Meanwhile, the Danish drugmaker was also bolstered by the decision by pharmacy benefit manager (PBM) CVS Health to remove Zepbound but retain Wegovy on its formulary of reimbursed medicines.

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...

CVS Health runs prescription drug coverage for ... of Medicine showing people lost more weight using competitor drug Zepbound, made by Eli Lilly of Indianapolis. The study, the first head-to ...